Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
EPOGEN/PROCRIT is a recombinant erythropoietin (EPO) cytokine approved in 1989 for stimulating red blood cell production in patients with anemia. It is administered via single-use vials and works by mimicking the natural hormone that regulates hemoglobin and hematocrit levels. The drug treats anemia associated with chronic kidney disease, chemotherapy, and other conditions causing reduced red blood cell production.
As LOE approaches, the brand team is likely contracting; careers here focus on maximizing existing market share and preparing for generic/biosimilar erosion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety of Erythropoietin and Melatonin for Very Preterm Infants With Intraventricular Hemorrhage
Incidence and Clinical Burden of Erythropoietin Hyporesponsiveness - a Retrospective Database Analysis
Impact of Erythropoietin on Hematological Adaptations and Physical Performance
A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD)
A Phase 2 Clinical Study of Pegerythropoietin Injection (RD01) for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis
Worked on EPOGEN/PROCRIT at Amgen? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on EPOGEN/PROCRIT as it approaches loss of exclusivity offers limited career acceleration; the role is primarily defensive and tactical. Team sizes are shrinking, making this a consolidation phase rather than a growth opportunity.